Thesis (Ph. D.)--Lehigh University, 2001. / Includes vita. Includes bibliographical references (leaves 127-165).

Thesis (M.D.)--University of Adelaide, Dept of Medicine, 1957. / Typewritten copy.

Thesis (Ph.D.)--University of Delaware, 2008. / Principal faculty advisor: Mary C. Farach-Carson, Dept. of Biological Sciences. Includes bibliographical references.

Univ., Diss., 2009--Marburg.

Thesis (Ph. D.)--University of Hong Kong, 2000. / Includes bibliographical references (leaves 205-240).

Hamburg, Universiẗat, Diss., 1999.

Orientador: Francisco Humberto de Abreu Maffei / Resumo: A heparina é um glicosaminoglicano sulfatado, de cadeia longa, que vem sendo largamente utilizada, desde meados do século passado, no tratamento e profilaxia das tromboses arteriais e venosas e cuja utilização permitiu o desenvolvimento das cirurgias cardíaca e vascular. As heparinas de baixo peso molecular (HBPM) são frações ou fragmentos da heparina separados do complexo polissacarídico por extração com solvente ou por gel filtração, ou por clivagem química ou enzimática aplicada antes dessa separação física. No presente artigo são revistos os diversos aspectos da estrutura, mecanismo de ação, farmacocinética, monitorização laboratorial e aplicações clínicas de ambos os tipos de substâncias, sendo chamada a atenção para as diferenças entre elas. As HBPM tendem a substituir a heparina não fracionada, na maior parte de suas indicações, por serem de mais simples utilização e apresentarem maior eficácia e segurança em algumas indicações, embora sejam de custo mais alto. / Abstract: Heparin is a long sulfated glucosaminoglicane chain has been used in the treatment and prophylaxis of arterial and venous thombosis since the 50's of last century. Its use also aided the development of cardiac and vascular surgery. Low molecular weight heparins (LMWH) are fractions or fragments of heparin separated from the polysaccharide complex by solvent extraction or gel filtration, or by chemical or enzymatic cleavage, before the extraction. In this article the main aspects of structure, mechanism of action, pharmacokinetics, laboratorial control, and clinical indications of both kinds of substances are reviewed and their main differences emphasized. Despite their high cost, LMWH presently tend to substitute unfractionated heparin in the majority of indications because of its simpler use, high efficacy and security in some cases. / Mestre

Made available in DSpace on 2014-06-11T19:23:41Z (GMT). No. of bitstreams: 0 Previous issue date: 2003Bitstream added on 2014-06-13T19:09:44Z : No. of bitstreams: 1 carelli_g_me_botfm.pdf: 357124 bytes, checksum: 5673f0ccb2732bdb65892b407c35e19c (MD5) / A heparina é um glicosaminoglicano sulfatado, de cadeia longa, que vem sendo largamente utilizada, desde meados do século passado, no tratamento e profilaxia das tromboses arteriais e venosas e cuja utilização permitiu o desenvolvimento das cirurgias cardíaca e vascular. As heparinas de baixo peso molecular (HBPM) são frações ou fragmentos da heparina separados do complexo polissacarídico por extração com solvente ou por gel filtração, ou por clivagem química ou enzimática aplicada antes dessa separação física. No presente artigo são revistos os diversos aspectos da estrutura, mecanismo de ação, farmacocinética, monitorização laboratorial e aplicações clínicas de ambos os tipos de substâncias, sendo chamada a atenção para as diferenças entre elas. As HBPM tendem a substituir a heparina não fracionada, na maior parte de suas indicações, por serem de mais simples utilização e apresentarem maior eficácia e segurança em algumas indicações, embora sejam de custo mais alto. / Heparin is a long sulfated glucosaminoglicane chain has been used in the treatment and prophylaxis of arterial and venous thombosis since the 50’s of last century. Its use also aided the development of cardiac and vascular surgery. Low molecular weight heparins (LMWH) are fractions or fragments of heparin separated from the polysaccharide complex by solvent extraction or gel filtration, or by chemical or enzymatic cleavage, before the extraction. In this article the main aspects of structure, mechanism of action, pharmacokinetics, laboratorial control, and clinical indications of both kinds of substances are reviewed and their main differences emphasized. Despite their high cost, LMWH presently tend to substitute unfractionated heparin in the majority of indications because of its simpler use, high efficacy and security in some cases.

No description available.

Class of 2015 Abstract / Objectives: The purpose of the study was to analyze the effect of a network wide computer system and the implementation of weight based dosing on heparin alert rates. Our central hypotheses was that the implementation of a network wide computer system will decrease alert rates for heparin infusions on smart pump infusion systems. Our rationale for this study was to evaluate methods to improve patient safety for high alert medications such as heparin. Methods: This was a before-after study design evaluating the effect of the intervention using data obtained by a smart pump infusion system. Heparin infusions at the university campus were analyzed for the effect of a network wide computer system, administered in the adult ICU or Med/Surg unit between July 2013-September 2013 and from January 2014-March 2014. Pump data from before the implementation of the network wide computer system was compared to the pump data obtained after the network wide computer system. Results: After the implementation of a hospital wide computerized physician order entry system, there was a statistically significant increase in heparin alert rates from 15.7 alerts per 100 infusions of heparin to an alert rate of 20.2 alerts per 100 infusions of heparin (P=0.001). Conclusions: The implementation of a network wide computerized physician order entry was associated with an increase in alert generation rate on smart pump infusion systems. Further studies are needed to elucidate this unexpected increase in alerts.